Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 10/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1587867 | 1.00 | CNR2 (0.45) | CNR2CYP2D6CYP2C19CYP1A2HDAC3 | |
| SCHEMBL1587368 | 1.00 | CNR2 (0.45) | CNR2CYP2D6CYP2C19CYP1A2HDAC3 | |
| SCHEMBL12796044 | 0.93 | HDAC3 (0.49) | CNR2CYP2D6CYP2C19CYP1A2HDAC3 | |
| SCHEMBL15397162 | 0.88 | CNR2 (0.46) | CNR2CYP2D6CYP2C19CYP1A2HDAC3 | |
| SCHEMBL1587831 | 0.87 | MAPT (0.49) | CNR2CYP2D6CYP2C19CYP1A2HDAC3 | |
| SCHEMBL1587842 | 0.87 | MAPT (0.49) | CNR2CYP2D6CYP2C19CYP1A2HDAC3 | |
| SCHEMBL1587833 | 0.87 | MAPT (0.49) | CNR2CYP2D6CYP2C19CYP1A2HDAC3 | |
| SCHEMBL3770097 | 0.81 | CDK2 (0.46) | CNR2HDAC1MAPK8MAPK9 | |
| SCHEMBL12795998 | 0.80 | MAPT (0.51) | CNR2CYP2D6CYP2C19CYP1A2HDAC3 | |
| SCHEMBL1587440 | 0.79 | HSD11B1 (0.61) | HDAC3HDAC1HDAC2HDAC6HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011049520-A1 | ADAMANTYL IMINOCARBONYL-SUBSTITUTED PYRIMIDINES AS INHIBITORS OF 1 1 BETAHSD1 | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | WO | disclosed |
| US-20110092526-A1 | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092526-A1 | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092526-A1 | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092526-A1 | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 | HSD11B1, HSD17B11, HSD3B1 | CNR2 3611/4885CYP2D6 44/4885CYP2C19 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.